Section Arrow
AEZS.NASDAQ
- AEterna Zentaris Inc
Quotes are at least 15-min delayed:2024/05/16 01:48 EDT
Last
 8.645
+0.2565 (+3.06%)
Day High 
8.83 
Prev. Close
8.3885 
1-M High
8.6 
Volume 
16.98K 
Bid
8.46
Ask
10
Day Low
8.3999 
Open
8.5386 
1-M Low
7.74 
Market Cap 
10.18M 
Currency USD 
P/E -- 
%Yield
10-SMA 8.09 
20-SMA 7.96 
50-SMA 8.05 
52-W High 12.8 
52-W Low 5.4404 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-13.64/-4.56
Enterprise Value
10.30M
Balance Sheet
Book Value Per Share
14.99
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
4.50M
Operating Revenue Per Share
7.18
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
DNAGinkgo Bioworks Holdings0.8391-0.0237-2.75%-- 
NVAXNovavax12.9-0.58-4.30%-- 
JAGXJaguar Health0.2551-0.0198-7.20%-- 
OCGNOcugen1.96+0.26+15.29%-- 
ARQTArcutis Biotherapeutics9.24+1.11+13.65%-- 
Quotes are at least 15-min delayed:2024/05/16 01:48 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success &safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland which generates key revenue, Ireland, Denmark, and others.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.